Faron Pharmaceutical said it is to present data on the response of melanoma sufferers in the ongoing MATINS trial of its novel cancer treatment bexmarilimab to the 18th Congress of the European Association of Dermato-Oncology (EADO).
The melanoma cohort is one of the ten advanced treatment-resistant solid tumour types included in Part II (110 patients) of the MATINS study, which is assessing the treatment as monotherapy for hard-to-treat cancers.
Faron already revealed there was a 30% clinical benefit rate in melanoma patients following treatment during the study (read more).
Additional analysis suggested 100% overall survival at 12-months for patients who experienced clinical benefit following treatment, Faron added.
“This rate of clinical benefit is particularly striking when you consider these are heavily pre-treated patients, all of whom were refractory to currently approved checkpoint inhibitor therapy," said Marie-Louise Fjällskog, Faron’s chief medical officer.
"Bexmarilimab's ability to ignite an immune response in these patients means that it may serve as a catalyst for the immune system allowing initially checkpoint inhibitor-resistant patients to become responsive to PD-1/L1 blockade."
EADO is being held in Seville between April 21 to April 23, 2022